Ocumension Therapeutics (HKG:1477)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.90
+0.16 (2.37%)
At close: Mar 10, 2026
43.75%
Market Cap 5.50B
Revenue (ttm) 595.79M
Net Income (ttm) -273.13M
Shares Out 815.38M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 680,000
Average Volume 905,105
Open 6.81
Previous Close 6.74
Day's Range 6.80 - 7.03
52-Week Range 3.91 - 12.23
Beta 0.52
RSI 46.34
Earnings Date Mar 27, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 505
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1477
Full Company Profile

Financial Performance

In 2024, Ocumension Therapeutics's revenue was 417.31 million, an increase of 69.38% compared to the previous year's 246.37 million. Losses were -268.27 million, -29.36% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.